Factors associated with early recurrence and death after esophagectomy for cancer

Journal of Surgical Oncology

Volumn 109, Issue 5, 2014, Pages 459-464

  Davies, Andrew R ^a,b,c,d   Pillai, Andrew ^a   Sinha, Pranab ^a   Sandhu, Harinderjeet ^a   Adeniran, Amina ^a   Mattsson, Fredrik ^c   Choudhury, Asif ^b   Forshaw, Matthew J ^a   Gossage, James A ^a,c   Lagergren, Jesper ^a,c,d   Allum, William H ^b   Mason, Robert C ^a,c,d  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

esophageal cancer; recurrence; surgery

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL FEATURE; COHORT ANALYSIS; DIGESTIVE SYSTEM CANCER; DISTANT METASTASIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HIGH RISK PATIENT; HUMAN; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; VERY ELDERLY;

ESOPHAGEAL CANCER; RECURRENCE; SURGERY;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LONDON; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897024124     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23511     Document Type: Article

References (36)

1. Zhu ZJ, Hu Y, Zhao YF, et al.: Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg 2011; 91: 1502-1508.
2. Dresner SM, Griffin SM:, Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87: 1426-1433.
3. Abate E, DeMeester SR, Zehetner J, et al.: Recurrence after esophagectomy for adenocarcinoma: Defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428-435.
4. Avery KN, Metcalfe C, Barham CP, et al.: Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surg 2007; 94: 1369-1376.
5. de Boer AG, van Lanschot JJ, van Sandick JW, et al.: Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 2004; 22: 4202-4208.
6. Djarv T, Lagergren J, Blazeby JM, et al.: Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 2008; 95: 1121-1126.
7. Derogar M, Lagergren P:, Health-related quality of life among 5-year survivors of esophageal cancer surgery: A prospective population-based study. J Clin Oncol 2012; 30: 413-418.
8. Mandard AM, Dalibard F, Mandard JC, et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
9. Lagergren J, Mattson F:, Diverging trends in recent population-based survival rates in oesophageal and gastric cancer. PLoS ONE 2012; 7: e41352.
10. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-1733.
11. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
12. Rice TW, Blackstone EH, Rusch VW:, 7th edition of the AJCC Cancer Staging Manual: Esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724.
13. Zhang X, Watson DI, Lally C, et al.: Endoscopic ultrasound for preoperative staging of esophageal carcinoma. Surg Endosc 2005; 19: 1618-1621.
14. Lightdale CJ, Kulkarni KG:, Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005; 23: 4483-4489.
15. Sloof GW:, Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol 2006; 20: 941-957.
16. Griffin JM, Reed CE, Denlinger CE:, Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer. Ann Thorac Surg 2012; 93: 1855-1859; discussion 1860.
17. Riddell AM, Davies DC, Allum WH, et al.: High-resolution MRI in evaluation of the surgical anatomy of the esophagus and posterior mediastinum. AJR Am J Roentgenol 2007; 188: W37-W43.
18. Riddell AM, Allum WH, Thompson JN, et al.: The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol 2007; 17: 391-399.
19. Puli SR, Reddy JB, Bechtold ML, et al.: Staging accuracy of esophageal cancer by endoscopic ultrasound: A meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490.
20. Eloubeidi MA, Cerfolio RJ, Bryant AS, et al.: Efficacy of endoscopic ultrasound in patients with esophageal cancer predicted to have N0 disease. Eur J Cardiothorac Surg 2011; 40: 636-641.
21. Miyata H, Yamasaki M, Takahashi T, et al.: Relevance of [(18) F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer. Br J Surg 2013; 100: 1490-1497.
22. Ott K, Weber W, Siewert JR:, The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006; 19: 433-442.
23. Wieder H, Weber W:, Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction. Eur J Nucl Med Mol Imaging 2009; 36: 158-159.
24. Wieder HA, Ott K, Lordick F, et al.: Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007; 34: 1925-1932.
25. Lordick F, Ott K, Krause BJ, et al.: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
26. Piessen G, Petyt G, Duhamel A, et al.: Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2013; 258: 66-76.
27. Guillem P, Triboulet JP:, Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005; 18: 146-150.
28. Crumley AB, Going JJ, Hilmy M, et al.: Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer. Ann Surg Oncol 2011; 18: 2604-2612.
29. Chan DS, Reid TD, Howell I, et al.: Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg 2013; 100: 456-464.
30. O'Farrell NJ, Donohoe CL, Muldoon C, et al.: Lack of independent significance of a close (<1 mm) circumferential resection margin involvement in esophageal and junctional cancer. Ann Surg Oncol 2013; 20: 2727-2733.
31. Salih T, Jose P, Mehta SP, et al.: Prognostic significance of cancer within 1 mm of the circumferential resection margin in oesophageal cancer patients following neo-adjuvant chemotherapy. Eur J Cardiothorac Surg, 2013; 43: 562-567.
32. Sjoquist KM, Burmeister BH, Smithers BM, et al.: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011; 12: 681-692.
33. Pantling AZ, Gossage JA, Mamidanna R, et al.: Outcomes from chemoradiotherapy for patients with esophageal cancer. Dis Esophagus 2011; 24: 172-176.
34. van Hagen P, Hulshof MC, van Lanschot JJ, et al.: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
35. Peters CJ, Rees JR, Hardwick RH, et al.: A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010; 139: 1995.e15-2004.e15.
36. Takahashi K, Miyashita M, Nomura T, et al.: Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus 2007; 20: 117-122.